Abstract:Hepatitis C virus (HCV) infection is of high prevalence among patients with chronic kidney disease (CKD). There are many unique features in anti-HCV treatment of CKD patients. With the advent of direct-acting antiviral agents (DAAs) and their widely application in clinic practice, the prognosis of CKD patients with HCV infection has been greatly improved. In recent years, rapid progress has been made in HCV treatment, and many DAAs have been approved for marketing in China. Therefore, based on The expert consensus for the diagnosis and treatment of hepatitis C virus infection in patients with chronic kidney disease published in 2019, combined with the domestic and foreign progress of clinical research and the national situation in China at present, a panel of experts specialized in nephrology, infectious disease, hepatology and infection control have updated and issued this guideline, to provide guidance for the standardized diagnosis and treatment of HCV infection in CKD patients.